Kezar Life Sciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics targeting immune-mediated diseases and cancer. Its primary product candidates include KZR-616, a selective immunoproteasome inhibitor in Phase 2 clinical trials for autoimmune diseases such as lupus nephritis, dermatomyositis, and polymyositis, as well as Phase 1b trials for systemic lupus erythematosus and lupus nephritis. The company’s pipeline also includes preclinical candidates like KZR-261, a protein secretion inhibitor, and KZR-TBD, targeting oncology and immunology indications. Kezar applies proprietary technology to modulate master regulators of cellular function, aiming to inhibit multiple drivers of disease through single-target therapies designed for significant clinical impact in challenging-to-treat diseases. Founded in 2015 and headquartered in South San Francisco, California, Kezar Life Sciences operates primarily in the United States but targets global markets in autoimmune and oncologic therapeutic segments. The company has focused on leveraging broad immunomodulatory activity to deliver treatments that provide clinical benefit without widespread immunosuppression. The KZR-616 candidate has demonstrated the ability to enable steroid tapering in autoimmune hepatitis patients, reflecting its potential therapeutic advantage. In the latest corporate developments, Kezar has experienced significant operational challenges, including the discontinuation of its lupus program due to clinical holds following patient deaths in trials of zetomipzomib, another small molecule therapy for autoimmune hepatitis. The FDA recently canceled a key Type C meeting to discuss the development plan for zetomipzomib, leading to a workforce reduction of approximately 70%, as the company explores strategic alternatives to address regulatory hurdles and resource constraints. Despite these setbacks, Kezar presented positive Phase IIa data showing that 36% of autoimmune hepatitis patients achieved biochemical remission with zetomipzomib and were able to reduce steroid use. The company also recently received an unsolicited non-binding acquisition proposal, which it has rejected, emphasizing its intent to pursue long-term development and strategic opportunities independently. Kezar Life Sciences combines expertise in molecular biology and medicinal chemistry to develop its small molecule pipeline, emphasizing innovation in autoimmunity and oncology with the goal of addressing unmet medical needs. The company maintains a focus on patient-centered outcomes and regulatory alignment amid its ongoing clinical and strategic efforts.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages
Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy